Jefferies analyst Clara Dong raised the firm’s price target on Aldeyra (ALDX) to $7 from $6 and keeps a Buy rating on the shares ahead of the PDUFA deadline of December 16 set for the resubmitted NDA for Reproxalap. The firm, which considers FDA approval in December as “a moderately low-risk event” with 60% odds of success, notes that Aldeyra maintains an option agreement with AbbVie (ABBV), which could provide the company a “substantial payment” as well as a strategic commercial pathway for Reproxalap.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra receives orphan designation from EMA for ADX-2191
- Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191
- Aldeyra granted fast track designation for ADX-2191 by FDA
- Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
- Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential